METHODS OF SCREENING FOR THERAPEUTIC AGENTS USING NOVEL APOPTOSIS-MODULATING PROTEINS

Abstract: The present invention provides methods to screen for anti-viral agents utilizing a novel family of apoptosis-modulating proteins.

Description: METHODS OF SCREENING FOR THERAPEUTIC AGENTS USING NOVEL APOPTOSIS-MODULATING PROTEINS TECHNICAL FIELD This invention relates to methods of screening for therapeutic agents using novel proteins with apoptosis-modulating activity. BACKGROUND ART Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Recent studies of apoptosis have implied that a common metabolic pathway leading to cell death may be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation and infection by human immunodeficiency virus (HIV). Wyllie (1980) Nature 284:555-556; Kanter et al. (1984) Biochem. Biophys. Res. Commun. 118:392-399; Duke and Cohen (1986) Lymphokine Res. 5:289-299; Tomei et al. (\9%%) Biochem. Biophys. Res. Commun. 755:324-331; Kruman et al. (1991) J. Cell. Physiol. 148:261-213; Ameisen and Capron (1991) Immunology Today 12:102; and Sheppard and Ascher (1992) J. AIDS 5:143. Agents that modulate the biological control of apoptosis thus have therapeutic utility in a wide variety of conditions. Apoptotic cell death is characterized by cellular shrinkage, chromatin condensation, cytoplasmic blebbing, increased membrane permeability and interchromosomal DNA cleavage. Kerr et al. (1992) FASEB J. 6:2450; and Cohen and Duke (1992) Ann. Rev. Immunol. 10:261. The blebs, small, membrane-encapsulated spheres that pinch off of the surface of apoptotic cells, may continue to produce superoxide radicals which damage surrounding cell tissue and may be involved in inflammatory processes. The Bcl-2 gene was discovered at the common chromosomal translocation site t(14:18) in follicular lymphomas and results in aberrant over-expression of bcl-2. Tsujimoto et al. (1984) Science 226:1097-1099; and Cleary et al. (1986) Cell 47:19-28. The normal function of bcl-2 is the prevention of apoptosis; unregulated expression of bcl-2 in B cells is thought to lead to increased numbers of proliferating B cells which may be a critical factor in the development of lymphoma. McDonnell and Korsmeyer (1991) Nature 349:254-256; and, for review see, Edgington (1993) Bio/Tech. 77:787-792. Bcl-2 is also capable of blocking of γ irradiation-induced cell death. Sentman et al. (1991) Cell 67:879- 888; and Strassen (1991) Cell 67:889-899. It is now known that bcl-2 inhibits most types of apoptotic cell death and is thought to function by regulating an antioxidant pathway at sites of free radical generation. Hockenbery et al. (1993) Cell 75:241-251. Apoptosis, a normal cellular event, can also be induced by pathological conditions and a variety of injuries. Apoptosis is involved in a wide variety of conditions including, but not limited to: cardiovascular disease; cancer regression; immunoregulation; viral diseases; anemia; neurological disorders; gastrointestinal disorders such as diarrhea and dysentery; diabetes; hair loss; rejection of organ transplants; prostate hypertrophy; obesity; ocular disorders; stress; and aging. Bcl-2 belongs to a family of proteins of which some have been cloned and sequenced. Williams and Smith (1993) Cell 74:111-119. Various Bcl-2 members have the ability to associate with one another as heterodimers. Oltvai et al. (1993) Cell 74:609-619; and Sato et al. (1994) Proc. Natl. Acad. Sci. USA 97:9238-9242. Additionally, BHRF1 displays a 25% sequence identity to Bcl-2 (Cleary et al. (1986) Cell 47:19-28) and has been shown by gene transfer studies to protect B cells from apoptosis. Henderson et al. (1993) Proc. Natl. Acad. Sci. USA 90:8479-8483. The herpesvirus family of viruses typically produce latent and recurrent infections. Herpesvirus genomes are composed of sequences with a short and a long region. Herpesvirus particles have a diameter from 180 nm to 200 nm. Many particles do not contain envelopes. Typically, the DNA is wrapped around an associated protein. The herpesvirus has a tendency to persist in a quiescent state for irregular periods of time. All references cited herein, both supra and infra, are hereby incorporated by reference herein. SUMMARY OF THE INVENTION Methods of screening for pharmaceutical agents that stimulate, as well as pharmaceutical agents that inhibit Bak and Bak-2 protein activity levels are provided. The methods include combining a Bak protein and a viral protein under conditions in which they interact to form a test sample, exposing the test sample to a potential therapeutic agent and monitoring the interaction of the proteins. Potential therapeutic agents which disrupt the interaction compared to control test samples to which no agent has been added are selected for further study. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 depicts the Bak cDNA nucleotide sequence and amino acid sequence encoded thereby. Figure 2 shows the sequence of the Bak-2 cDNA and flanking sequences and the corresponding predicted amino acid sequence of the Bak-2 protein. Figure 3 shows the interactions of Bak and Flag-Bak (F-Bak) fusion proteins with Epstein-Barr virus BHRF-1 protein. In column A, lane 1 depicts the results obtained from in vitro co-translated proteins F-Bak/BHRF-1 and lane 2 depicts F-Bak/BHRF-1 proteins bound to anti-FLAG agarose. In column B, the lanes are the same with the exception that the Bak protein is Bak-2. DISCLOSURE OF THE INVENTION The present invention provides methods of screening for potential anti¬ viral therapeutic agents. The proteins encoded by nucleotide sequences encoding the novel bcl-2 homologs, Bak and Bak-2 proteins have been found to interact with the Epstein Barr Virus (EBV) protein BHRFl indicating that Bak proteins contribute to the pathogenicity of the disease. BHRFl is an EBV early lytic cycle protein. Pearson et al. (1987) Virol. 760:151-161. The invention encompasses methods containing the steps of exposing the Bak proteins and viral proteins, or functional portions thereof, to potential therapeutic agents and monitoring the interaction of the proteins. The invention further utilizes recombinant cells and transgenic animals expressing the cloned Bak or Bak-2 genes. The cloning and analysis of Bak genes and proteins are described in detail in commonly owned WO application PCT/US94/13930. Bak genes and proteins are also described in Kiefer et al. (1995) Nature 374:136. The nucleotide and predicted amino acid residue sequences of Bak protein are shown in Figure 1 ; and those of Bak-2 are shown in Figure 2. Bak mR A has been detected in a variety of human organs and tissues by Northern blot analysis. These organs include liver; heart; skeletal muscle; lung; kidney; and pancreas. These references also disclose that the Bak proteins are capable of modulating apoptosis. In a lymphoblastoid cell line, expression of Bak protein was shown to decrease Fas-mediated apoptosis. In a mouse progenitor B cell line, FL5.12, Bak-2 protein and a derivative of Bak protein decrease IL-3-induced apoptosis whereas Bak protein increased apoptosis. Thus, depending on the cell type, the derivative of Bak protein, and the method of induction of apoptosis, apoptosis can be modulated in a highly specific manner by controlling the concentration of Bak proteins. As used herein, the term "Bak gene(s)" refers to the nucleic acid molecules described herein and in PCT US94/13930, "the Bak protein(s)" refers to the proteins encoded thereby. The nucleotides include, but are not limited to, the cDNA and complementary DNA, genome-derived DNA and synthetic or semi- synthetic DNA or RNA. The nucleotide sequence of the Bak cDNA with the location of restriction endonuclease sites is shown in Figure 1. The nucleotide sequence of Bak-2 cDNA, along with the predicted amino acid sequence of Bak-2 protein and the locations of restriction endonuclease recognition sites, is given in Figure 2. The Bak gene is on human chromosome 6 and the Bak-2 gene is on human chromosome 20. There is also a member of the family, Bak-3, which is on human chromosome 11. Bak-3 appears to be a pseudogene. Fluorescence in situ hybridization (FISH) indicated an approximate location of the Bak gene to be at 6p21 -23. The invention includes the use of modified Bak DNA sequences such as deletions, substitutions and additions particularly in the non-coding regions of genomic DNA. Such changes are useful to facilitate cloning and modify gene expression. Any DNA which encodes a portion of a Bak protein sufficient to bind to BHRFl or any other suitable viral protein is suitable for use herein. As described below, various fusion proteins are suitable for use herein. Various substitutions can be made within the coding region that either do not alter the amino acid residues encoded or result in conservatively substituted amino acid residues. Nucleotide substitutions that do not alter the amino acid residues encoded are useful for optimizing gene expression in different systems. Suitable substitutions are known to those of skill in the art and are made, for instance, to reflect preferred codon usage in the particular expression systems. The invention encompasses the use of functionally equivalent variants and derivatives of Bak genes which may enhance, decrease or not significantly affect the properties of Bak proteins. For instance, changes in the DNA sequence that do not change the encoded amino acid sequence, as well as those that result in conservative substitutions of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogs are those which will not significantly affect its properties. Amino acid residues which can be conservatively substituted for one another include but are not limited to: glycine/alanine; valine/isoleucine/leucine; asparagine/glutamine; aspartic acid/glutamic acid; serine/threonine; lysine/arginine; and phenylalanine/tyrosine. Any conservative amino acid substitution which does not significantly affect the properties of Bak proteins is encompassed by the present invention. Techniques for nucleic acid manipulation useful for the practice of the present invention are described in a variety of references, including, but not limited to, Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, eds. Sambrook et al, Cold Spring Harbor Laboratory Press (1989); and Current Protocols in Molecular Biology, eds. Ausubel et al, Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates. The coding regions of Bak genes can also be ligated into expression vectors capable of stably integrating into other cell types including but not limited to cardiomyocytes, neural cell lines such as GTI-7 and TNF sensitive cells such as the human colon adenocarcinoma cell line HT29 so as to provide a variety of assay systems to monitor the regulation of apoptosis by Bak proteins. As used herein, "BHRFl" or "viral proteins" encompasses the full length EBV protein and portions or derivations thereof sufficient to bind to Bak proteins or portions or derivatives thereof. Such proteins include, but are not limited to, homologous proteins expressed by any virus, particularly various forms of heφes and herpes-like viruses, such as cytomegalovirus and varicella zoster. The interaction between a Bak protein and viral protein such as BHRF-1 can be produced by adding purified proteins together. Preferably, however, the proteins are cotranscribed and translated under conditions that allow protein- protein interactions. Co-translation can be performed in vitro or in vivo in whole cells expressing native or recombinant Bak proteins and viral proteins. Any suitable recombinant expression vectors may be used. The Bak proteins can also be separately translated and then combined under conditions that allow for protein-protein interactions. Methods of monitoring protein interactions are known in the art, any method is suitable for use herein. Preferably, co-precipitation is used. The ability of an antibody to precipitate one of the proteins or an immunological tag fused thereto is used to immunoprecipitate the protein and the immunoprecipitate is monitored for the presence of both proteins. Methods of co-precipitation are known in the art and are described in the examples below. Any other method in the art is suitable for use herein, including, but not limited to, protein interactive trapping, such as GST fusion protein immobilization on glutathione columns and, ELISA. Immunological tags are often incoφorated into fusion proteins and including, for instance, FLAG, hemagglutinin and glutathione-S transferase. Purification or isolation of Bak proteins expressed either by the recombinant DNA or from biological sources such as tissues can be accomplished by any method known in the art. Protein purification methods are known in the art. Generally, substantially purified proteins are those which are free of other, contaminating cellular substances, particularly proteins. Preferably, the purified Bak proteins are more than eighty percent pure and, most preferably, more than ninety-five percent pure. For clinical use as described below, the Bak proteins are preferably highly purified, at least about ninety-nine percent pure, and free of pyrogens and other contaminants. Suitable methods of protein purification are known in the art and include, but are not limited to, affinity chromatography, immunoaffinity chromatography, size exclusion chromatography, HPLC and FPLC. Any purification scheme that does not result in substantial degradation of the protein is suitable for use herein. As used herein, "Bak proteins" includes functionally equivalent variants thereof which do not significantly affect their properties and variants which retain the same overall amino acid sequence but which have enhanced or decreased activity. For instance, conservative substitutions of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogs are within the scope of the invention. Amino acid residues which can be conservatively substituted for one another include but are not limited to: glycine/alanine; valine/isoleucine/leucine; asparagine/glutamine; aspartic acid/glutamic acid; serine/threonine; lysine/arginine; and phenylalanine/tyrosine. Any conservative amino acid substitution which does not significantly affect the properties of Bak proteins is encompassed by the present invention. Suitable antibodies for use herein are generated by using the Bak proteins as an antigen or, preferably, peptides encompassing the Bak protein regions that lack substantial homology to the other gene products of the bcl family. Antibodies to the viral proteins are also suitable for use herein. Methods of detecting proteins using antibodies and of generating antibodies using proteins or synthetic peptides are known in the art and are not described in detail herein. Screening for therapeutically effective agents is done by exposing the Bak protein and the viral protein to such agents which may directly or indirectly affect the interaction between a Bak protein and a viral protein. Suitable potential therapeutic agents include, but are not limited to, any pharmaceutical agent such as cytokines, small molecule drugs, cell-permeable small molecule drugs, hormones, combinations of interleukins, lectins and other stimulating agents, e.g., PMA, LPS, bispecific antibodies, peptide mimetics, antisense oligonucleotides and other agents which modify cellular functions or protein expression. The proteins are added together or co-expressed, exposed to such agents at physiologically effective concentrations, and the interaction thereof is measured relative to a control not exposed to such agents. Those biological modifiers which decrease the interaction between a Bak protein and a viral protein relative to a control are selected for further study of their anti-viral activity. As previously shown, overexpressed Bak proteins protect EBV- transformed B cells from apoptosis following serum withdrawal or anti-Fas treatment. PCT/US94/13930. These results indicate that a Bak-BHRFl interaction exists whereby BHFR1 not only neutralizes the normally apoptotic effect of Bak protein, but additionally induces a protective activity. Alternatively, propagation of cells transfected with the Bak cDNA might select for cells that are expressing high levels of BHRFl or other EBV encoded anti-apoptotic proteins. This could lead to an anti-apoptotic response upon subjecting the cells to an apoptosis signal such as serum withdrawal. Example 2 shows that in vitro translated Flag-Bak (epitope tagged) and BHRFl can be coprecipitated with an antibody that recognizes the Flag epitope indicating that Bak proteins and BHRFl interact directly with one another. The following examples are provided to illustrate but not limit the present invention. Unless otherwise specified, all cloning techniques were essentially as described by Sambrook et al. (1989) and all reagents were used according to the manufacturer's instructions. Example 1 Expression of Recombinant Bak Gene In order to express the recombinant Bak gene in the baculovirus system, the Bak cDNA generated as described in PCT US94/1 930 was used to generate a novel Bak vector, by PCR, using primers from the 3' and 5' flanking regions of the gene which contain restriction sites to facilitate cloning. The plasmids were sequenced by the dideoxy terminator method (Sanger et al. , 1977) using sequencing kits (USB, Sequenase version 2.0) and internal primers. This was to confirm that no mutations resulted from PCR. A clone was used to generate recombinant viruses by in vivo homologous recombination between the overlapping sequences of the plasmid and AcNPV wild type baculovirus. After 48 hours post-transfection in insect Spodoptera frugiperda clone 9 (SF9) cells, the recombinant viruses were collected, identified by PCR and further purified. Standard procedures for selection, screening and propagation of recombinant baculovirus were performed in accordance with the manufacturer's instructions (Invitrogen). The molecular mass, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), of the protein produced in the baculovirus system was compared with the predicted molecular mass of Bak protein according to the amino-acid sequence. In addition, similar clones can be expressed in any expression system known in the art including, but not limited to, bacterial, yeast, insect and mammalian. A suitable yeast intracellular expression system is described by Barr et al. (1992) Transgenesis ed. JAH Murray, (Wiley and Sons) pp. 55-79. The Bak gene coding sequence was excised and introduced into plasmids pCEP7, pREP7 and pcDNA3 (Invitrogen) at compatible restriction enzyme sites. pCEP7 was generated by removing the RSV 3*-LTR of pREP7 with Xbal/AspllZ, and substituting the CMV promoter from pCEP4 (Invitrogen). 25 μg of each Bak-containing plasmid was electroporated into the B lymphoblastoid cell line WIL-2, and stable hygromycin resistant transformants or G418 resistant transformants (pcDNA3 constructs) expressing Bak were selected. Example 2 Bak proteins interact with Epstein-Barr Virus encoded BHRFl protein BHRFl cDNA was amplified by RT-PCR from WI-L2 mRNA using standard PCR protocol according to the instructions of the manufacturers of the PCR kit and thermal cycler (Perkin Elmer Cetus). The Flag-Bak and Flag-Bak-2 cDNAs were generated by RT-PCR as above from Bak and Bak-2/pcDNA3 plasmid templates but included the 24 base Flag encoding sequence 5'-GAC TAC AAG GAC GAC GAT GAC AAG-3' in the sense primer. This resulted in a cDNA encoding N-terminal Flag-Bak and Flag-Bak-2 fusion proteins that could be recognized and purified by the anti-Flag M2 antibody (Kodak-IBI). The cDNAs were ligated into the pcDNA3 vector which is under the control of the CMV and T7 RNA polymerase promoter. The Flag-Bak and BHRFl plasmids or Flag-Bak-2 and BHRFl plasmids were then cotranscribed and cotranslated using the TnT coupled reticulocyte lysate system according to manufacturer's instructions (Promega). Briefly, 0.5-1.0 μg of the two circular plasmids were simultaneously transcribed and translated in 50 μL of TnT lysate for 90 minutes at 32°C. After translation, 20 μL of lysate was mixed with 20 μL of 2X PBS plus 40 μL of anti- Flag M2 affinity gel (Kodak) and incubated with gentle rocking overnight at 4°C. Immunoprecipitates were collected by centrifugation in an Eppendorf microfuge at 1500 φm for 15 minutes at 4°C. Pellets were washed 4 times with 1.5 mL PBS and after the final wash were resuspended in 30 μL of SDS-PAGE sample buffer. The samples were then analyzed by SDS-PAGE on a 18% polyacrylamide gel. Gels were fixed with 10% glacial acetic acid, dried and exposed to X-ray film overnight at room temperature. As shown in Figure 3, Flag-Bak and BHRFl as well as Flag-Bak-2 and BHRFl were efficiently cotranscribed and cotranslated (lanes 1). Clearly, the anti-Flag M2 antibody effectively coprecipitates Flag-Bak and BHRFl or Flag- Bak-2 and BHRFl (lanes 2). This demonstrates that BHRFl interacts with both Bak and Bak-2 proteins in vitro and suggests that such interactions occur in vivo resulting in the modulation of apoptosis. Interactions of Bak proteins with viral proteins are likely to have evolved to allow viral replication or latency to proceed in the absence of apoptotic death of the host cell. Interference, therefore, in these interactions represents an important new strategy for the design of novel antiviral agents. Similarly, malignant cells derived from transformation by viruses such as EBV would also be amenable to diagnosis or therapy with these agents. Although the foregoing invention has been described in some detail by way of illustration and example for puφoses of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

Claims: CLAIMS We claim: 1. A method for screening potential anti-viral therapeutic agents i comprising the steps of: (a) combining a Bak protein and a viral protein under conditions in which they interact, to form a test sample; (b) exposing the test sample to a potential therapeutic agent and; ) (c) monitoring the interaction of the Bak protein and the viral protein; wherein, a potential therapeutic agent is selected for further study when it disrupts the interaction compared to a control test sample to which no potential therapeutic agent has been added. 2. The method according to claim 1 , wherein the potential therapeutic agent is selected from the group consisting of any pharmaceutical agent, cytokines, small molecule drugs, cell-permeable small molecule drugs, hormones, combinations of interleukins, lectins and other stimulating agents e.g. PMA, LPS, bispecific antibodies, peptide mimetics, antisense oligonucleotides and other agents which modify cellular functions or protein expression. 3. The method according to claim 1, wherein the Bak protein is selected from the group consisting of Bak, Bak-2, portions thereof sufficient to effect binding to a viral protein and fusion proteins thereof containing a portion thereof sufficient to effect binding to a viral protein. 4. The method according to claim 3, wherein the fusion protein is selected from the group consisting of epitope-tagged Bak protein and epitope- tagged Bak-2 protein. 5. The method according to claim 1 , wherein the viral protein is- selected from the group consisting of Epstein Barr Virus BHRFl protein, other EBV encoded anti-apoptotic proteins and proteins homologous to BHRFl expressed by heφes viruses and heφes-like viruses. 6. The method according to claim 1, wherein the monitoring step is by a method selected from the group consisting of co-precipitation, protein interactive trapping and ELISA.

Inventors: BARR PHILIP J, KIEFER MICHAEL C, BARR, PHILIP, J., KIEFER, MICHAEL, C.
Applicants: BARR PHILIP J, KIEFER MICHAEL C, LXR BIOTECHNOLOGY INC, BARR, PHILIP, J., KIEFER, MICHAEL, C., LXR BIOTECHNOLOGY INC.
Application year: 1996
Main classification: G01N33
IPC codes: A61K38, A61K45, A61P31, C07K14, G01N33